CervoMed and Cognition Therapeutics testing different therapeutic hypotheses in dementia with Lewy bodies

With Karuna’s PDUFA date and several readouts on the way, 2024 is still looking like an important year for progress in treating the disease

A look ahead to the schizophrenia milestones coming this year, and the mechanisms behind them

Plus: Translational inhibition company Initial launches with $75M from ATP and updates from Biogen, Ascendis, Minerva, Teva-MedinCell, BMS, Avadel

Biogen’s ALS candidate delayed, plus updates from Oculis, Treeline, Minerva, Acrivon and more

Minerva nears make-or-break readouts from its two founding neuropsychiatry programs

How Cognition plans to protect synapse function in AD via sigma-2